pmid,title,percents,n_percents,min,max,mean,context_snippets
40844110,"Multicentric validation of the PathoDetect™ MTB RIF & INH assay for simultaneous detection of Mycobacterium tuberculosis, & drug resistance to rifampicin & isoniazid in presumptive pulmonary tuberculosis & drug-resistant TB patients.",95; 95; 95; 95; 95; 95; 95; 95; 95; 95; 95; 95; 88.8; 93.9; 86.8; 94.9,16,86.8,95.0,94.025,"showed a sensitivity of 98.1 per cent [95% confidence interval (CI): 96.1-99.2], s | .1-99.2], specificity of 94.2 per cent (95% CI: 91-96.5), PPV of 94.9 per cent (95% | 95% CI: 91-96.5), PPV of 94.9 per cent (95% CI: 92.2-96.9), and NPV of 97.8 per cen | : 92.2-96.9), and NPV of 97.8 per cent (95% CI: 95.5-99.1) with near-perfect agreem | ce with a sensitivity of 86.5 per cent (95% CI: 80.2-91.5), specificity of 91.6 per | .2-91.5), specificity of 91.6 per cent (95% CI: 88.2-94.3), PPV of 82.3 per cent (9 | % CI: 88.2-94.3), PPV of 82.3 per cent (95% CI: 75.6-87.8), and NPV of 93.8 per cen | : 75.6-87.8), and NPV of 93.8 per cent (95% CI: 90.7-96.1). For INH resistance, sen | istance, sensitivity was 88.9 per cent (95% CI: 84.1-92.6), specificity 87 per cent | I: 84.1-92.6), specificity 87 per cent (95% CI: 82.4-90.8), PPV 85.6 per cent (95% | (95% CI: 82.4-90.8), PPV 85.6 per cent (95% CI: 80.5-89.8), and NPV 90 per cent (95 | 5% CI: 80.5-89.8), and NPV 90 per cent (95% CI: 85.7-93.4) using pDST as reference. | monstrated higher sensitivity (93.4 vs. 88.8%), specificity (98.2 vs. 93.9%), PPV (96 | (93.4 vs. 88.8%), specificity (98.2 vs. 93.9%), PPV (96.1 vs. 86.8%) and NPV (97 vs. | ificity (98.2 vs. 93.9%), PPV (96.1 vs. 86.8%) and NPV (97 vs. 94.9%) for RIF resista | ), PPV (96.1 vs. 86.8%) and NPV (97 vs. 94.9%) for RIF resistance detection over True"
40683298,"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.",12; 31; 46; 54; 64; 29; 71; 91; 87; 89; 2; 95,12,2.0,95.0,55.916666666666664,"bles, with a non-inferiority margin of -12%. This trial is registered with Clinical | 1030 individuals were screened and 324 (31%) were randomly assigned (219 to the BDL | oup and 105 to the control group). 114 (46%) participants were female and 133 (54%) | (46%) participants were female and 133 (54%) were male. Median age was 30·5 years ( | ge was 30·5 years (IQR 21·6-43·0). 157 (64%) participants had extensive disease at | ase at baseline. In the BDLC group, 47 (29%) of 163 were assigned to receive the 6- | to receive the 6-month regimen and 116 (71%) the 9-month regimen. The core regimen | ne or more other drugs was used for 76 (91%) of 84 participants in the control grou | favourable outcome was reached by 141 (87%) participants in the BDLC group versus | rticipants in the BDLC group versus 75 (89%) in the control group in the mITT popul | population (adjusted risk difference 0·2% [95% CI -9·1 to 9·5]; p The shortened B | ulation (adjusted risk difference 0·2% [95% CI -9·1 to 9·5]; p The shortened BDLC s"
40672039,Prognostic Value of Time-to-Positivity and Cycle Threshold (CT) Values in Predicting Tuberculosis Outcomes and Multidrug Resistance in Northern India: A Study Using Liquid Culture and Molecular Diagnostics.,52.8,1,52.8,52.8,52.8,outcomes. MGIT culture was positive in 52.8% (38/72) of patients (mean TTP: 26.5 day
40669825,"Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India.",6.7; 32.4; 42.2; 14.4; 81.5; 77; 67.5; 59.2; 48; 17.3; 10; 3.3; 2.2; 9.4; 92; 82.5; 93.6; 68.2; 61.9; 30.7; 53.8; 15.2; 38.4; 0; 69.5; 68.2; 46.3; 46.3; 24.3; 74; 62.9; 48.1; 40.7; 26.9,34,0.0,93.6,44.54705882352941,"neage of lineage 1, 2, 3 and 4 were 13 (6.7 %), 63 (32.4 %), 82 (42.2 %) and 28 (14.4 | eage 1, 2, 3 and 4 were 13 (6.7 %), 63 (32.4 %), 82 (42.2 %) and 28 (14.4 %) respectiv | and 4 were 13 (6.7 %), 63 (32.4 %), 82 (42.2 %) and 28 (14.4 %) respectively. Out of t | .7 %), 63 (32.4 %), 82 (42.2 %) and 28 (14.4 %) respectively. Out of total 194 culture | r single or in combinations: rpoB (146, 81.5 %), katG (138, 77 %), pncA (62, 34.6), gy | nations: rpoB (146, 81.5 %), katG (138, 77 %), pncA (62, 34.6), gyrA (121, 67.5 %), | 138, 77 %), pncA (62, 34.6), gyrA (121, 67.5 %), embB (106, 59.2 %), rpsL (86,48 %) fo | , 34.6), gyrA (121, 67.5 %), embB (106, 59.2 %), rpsL (86,48 %) followed by fabG1 (31, | , 67.5 %), embB (106, 59.2 %), rpsL (86,48 %) followed by fabG1 (31, 17.3 %), embA ( | , rpsL (86,48 %) followed by fabG1 (31, 17.3 %), embA (18,10 %), gid (6,3.3 %), inhA ( | ollowed by fabG1 (31, 17.3 %), embA (18,10 %), gid (6,3.3 %), inhA (4), eis (4,2.2 % | G1 (31, 17.3 %), embA (18,10 %), gid (6,3.3 %), inhA (4), eis (4,2.2 %), rrs (17, 9.4 | ,10 %), gid (6,3.3 %), inhA (4), eis (4,2.2 %), rrs (17, 9.4 %). Lineage 2 was found | 3 %), inhA (4), eis (4,2.2 %), rrs (17, 9.4 %). Lineage 2 was found to be most mutate | gyrA, embB, and pncA gene mutations was 92 %, 82.5 %, 93.6 %, 68.2 %, and 61.9 %, re | embB, and pncA gene mutations was 92 %, 82.5 %, 93.6 %, 68.2 %, and 61.9 %, respective | d pncA gene mutations was 92 %, 82.5 %, 93.6 %, 68.2 %, and 61.9 %, respectively. This | ene mutations was 92 %, 82.5 %, 93.6 %, 68.2 %, and 61.9 %, respectively. This was hig | s was 92 %, 82.5 %, 93.6 %, 68.2 %, and 61.9 %, respectively. This was higher than in | ely. This was higher than in lineage 1 (30.7 %, 53.8 %, 15.2 %, 38.4 %, 0 % respective | s was higher than in lineage 1 (30.7 %, 53.8 %, 15.2 %, 38.4 %, 0 % respectively), lin | gher than in lineage 1 (30.7 %, 53.8 %, 15.2 %, 38.4 %, 0 % respectively), lineage 3 ( | n in lineage 1 (30.7 %, 53.8 %, 15.2 %, 38.4 %, 0 % respectively), lineage 3 (69.5 %, | eage 1 (30.7 %, 53.8 %, 15.2 %, 38.4 %, 0 % respectively), lineage 3 (69.5 %, 68.2 | , 38.4 %, 0 % respectively), lineage 3 (69.5 %, 68.2 %, 46.3 %, 46.3 %, 24.3 % respect | , 0 % respectively), lineage 3 (69.5 %, 68.2 %, 46.3 %, 46.3 %, 24.3 % respectively), | spectively), lineage 3 (69.5 %, 68.2 %, 46.3 %, 46.3 %, 24.3 % respectively), and Euro | ly), lineage 3 (69.5 %, 68.2 %, 46.3 %, 46.3 %, 24.3 % respectively), and Euro-America | eage 3 (69.5 %, 68.2 %, 46.3 %, 46.3 %, 24.3 % respectively), and Euro-American lineag | ectively), and Euro-American lineage 4 (74 %, 62.9 %, 48.1 %, 40.7 %, 26.9 % respect | ly), and Euro-American lineage 4 (74 %, 62.9 %, 48.1 %, 40.7 %, 26.9 % respectively). | Euro-American lineage 4 (74 %, 62.9 %, 48.1 %, 40.7 %, 26.9 % respectively). Based on | erican lineage 4 (74 %, 62.9 %, 48.1 %, 40.7 %, 26.9 % respectively). Based on this st | ineage 4 (74 %, 62.9 %, 48.1 %, 40.7 %, 26.9 % respectively). Based on this study, lin"
40540654,Diagnostic Modalities for Detecting Extrapulmonary Tuberculosis and Resistance Patterns of Rifampicin and Isoniazid at a Referral Hospital: A Retro Prospective Study.,11.9; 6.4; 29; 4.13; 4.13,5,4.13,29.0,11.112,"detected M. tuberculosis in 339 cases (11.9%), significantly outperforming microscop | ly outperforming microscopy (183 cases, 6.4%). The highest positivity rates occurred | ssue biopsies and lymph node aspirates (29%), while genitourinary TB was least freq | resistance was identified in 14 cases (4.13%), all confirmed as multidrug-resistant | e settings. The high MDR-TB prevalence (4.13%) underscores the need for rapid molecul"
40518218,Empowering care: Unleashing pharmaceutical care to confront MDR-TB transmission risks-A prospective interventional study.,47.50; 67.50; 32.5; 7.50; 26.67; 50; 33.33; 24.17; 5,9,5.0,67.5,32.68555555555556,"trict, Karnataka. India. Most patients (47.50%) were aged 25-44 years. Of the 120 MDR- | 5-44 years. Of the 120 MDR-TB patients, 67.50% are male and 32.5% are female. Of 120 M | 20 MDR-TB patients, 67.50% are male and 32.5% are female. Of 120 MDR-TB patients, 7.5 | .5% are female. Of 120 MDR-TB patients, 7.50% are HIV positive. As part of the study, | ositive. As part of the study, smoking (26.67%), chewing tobacco (50%), and alcohol co | udy, smoking (26.67%), chewing tobacco (50%), and alcohol consumption (33.33%) were | tobacco (50%), and alcohol consumption (33.33%) were found to be other major risk fact | e found to be other major risk factors. 24.17% of patients had a family history of tub | amily history of tuberculosis, of which 5% had contact with an infected person as"
40354869,Characterisation of M. tuberculosis isolates obtained from Tamil Nadu prevalence survey by whole genome sequencing analysis.,57.2; 37.9; 85.9; 90; 77; 87,6,37.9,90.0,72.5,"ther characterisation, out of which 71 (57.2 %) and 47 (37.9 %) were subjected to sequ | ation, out of which 71 (57.2 %) and 47 (37.9 %) were subjected to sequencing and pheno | sequencing data were available for 61 (85.9 %), where the lineage distribution and dr | n pDST and gDST for the drugs was above 90 % except for ETH (77 %) and INH (87 %). T | he drugs was above 90 % except for ETH (77 %) and INH (87 %). The phylogenetic analy | ove 90 % except for ETH (77 %) and INH (87 %). The phylogenetic analysis of the line"
40079698,Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study.,36; 54; 94; 95; 95; 95; 87; 40; 40; 8,10,8.0,95.0,64.4,"s from December 2020-December 2022, 42 (36%) exhibited a BDQ-resistant strain. Medi | IQR) age was 24 (22-32) years, with 63 (54%) females and 94% with pulmonary TB. Pat | 22-32) years, with 63 (54%) females and 94% with pulmonary TB. Patients with a BDQ- | ve lung cavities (risk ratio [RR]: 1.8; 95%-CI: 1.1-3.1; P = .02), and be resistant | d be resistant to clofazimine (RR: 2.3; 95%-CI: 1.5-3.6; P = .001). Overall, 102 pa | with BDQ-susceptible patients (RR:2.1; 95%-CI: 1.5-2.8; P < .001). Overall, 87% (3 | 1; 95%-CI: 1.5-2.8; P < .001). Overall, 87% (33/38) of patients with BDQ-resistance | ced unfavorable treatment outcomes: 15 (40%) died, 15 (40%) had treatment failure, | treatment outcomes: 15 (40%) died, 15 (40%) had treatment failure, and 3 (8%) were | 15 (40%) had treatment failure, and 3 (8%) were lost-to-follow-up. The study high"
40053148,Prevalence and Genetic Profiling of Second-line Drug Resistant Tuberculosis at the Tertiary Care Center of Northern India.,28.62; 89.04; 4.11; 6.8; 60.37; 39.72; 71.23; 13.69; 5.48; 9.58; 1.37,11,1.37,89.04,30.00090909090909,"MDR/RR-TB patients were analyzed and 73(28.62%) patients exhibited second-line drug (S | g (SLD) resistance. Among the cases, 65(89.04%) were found to be resistant solely to f | ely to fluoroquinolones (FQ), whereas 3(4.11%) were resistant only to aminoglycosides | minoglycosides (pre-XDR TB). However, 5(6.8%) patients were resistant to both FQ and | s (XDR-TB). We also found that males 44(60.37%) were more affected by SLD resistance t | more affected by SLD resistance than 29(39.72%) females, however SLD resistant females | gene was D94G, which was observed in 52(71.23%) cases, followed by A90V in 10(13.69%), | 2(71.23%) cases, followed by A90V in 10(13.69%), D94N and D94A in 4(5.48%), whereas th | A90V in 10(13.69%), D94N and D94A in 4(5.48%), whereas the rrs gene presented the rr | nted the rrsMUT1 (A1401G) mutation in 7(9.58%) and the rrsMUT2(G1484T) mutation in 1( | ) and the rrsMUT2(G1484T) mutation in 1(1.37%) of SLD-resistant patients. The alarmin"
40013634,Newer research transforming 24-month treatment of MDR/XDR-TB TO 6 months.,80; 90,2,80.0,90.0,85.0,"0; the aim is to reduce TB incidence by 80% and TB deaths by 90%. To eliminate the | ce TB incidence by 80% and TB deaths by 90%. To eliminate the catastrophic cost, th"
39497757,"Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study.",27; 7; 54; 88; 87; 52; 35; 2.3; 9.2; 1.8; 13; 5,12,1.8,88.0,31.775000000000002,"ity globally, with India accounting for 27% of the estimated number of people with | sistant TB initiated on treatment, 217 (7 %) had INH mono-resistant TB. Of these, 5 | %) had INH mono-resistant TB. Of these, 54 % (117/217) were female, with a median ag | erquartile range: 20-40). The majority (88 %; 191/217) presented with pulmonary TB, | presented with pulmonary TB, and most (87 %; 188/217) had favourable treatment outc | tcomes, including treatment completion (52 %; 112/217) and cure (35 %; 76/217). Unfa | nt completion (52 %; 112/217) and cure (35 %; 76/217). Unfavourable outcomes, includ | outcomes, including treatment failure (2.3 %; 5/217), loss to follow-up (9.2 %; 20/2 | lure (2.3 %; 5/217), loss to follow-up (9.2 %; 20/217), or death (1.8 %; 4/217), were | to follow-up (9.2 %; 20/217), or death (1.8 %; 4/217), were observed in 13 % (29/217) | death (1.8 %; 4/217), were observed in 13 % (29/217) of patients. A total of ten (5 | % (29/217) of patients. A total of ten (5 %) patients experienced at least one non-"
39278675,Comparative study of infection control practices in DOTS/sputum microscopy centre in two different districts of state of Uttarakhand and Uttar Pradesh of India.,100; 66.66; 57.14; 55.56; 21.43; 27.78; 33.33; 28.57,8,21.43,100.0,48.80875,"centres of both selected districts i.e. 100% sample size are covered in the study. H | trol of infection. In Dehradun district 66.66% (12) centers and in Ghaziabad district | (12) centers and in Ghaziabad district 57.14% (16) centers have adequate hand washing | to the infection. In Dehradun district, 55.56% (10) centers have adequate PPE availabl | available whereas in Ghaziabad District 21.43% (6) centers have adequate PPE available | on and control for HCWs are provided in 27.78% (5) DOTS/sputum microscopy center in De | ventilation in their working places. In 33.33% (6) DOTS/sputum microscopy center in De | /sputum microscopy center in Dehradun & 28.57% (8) in Ghaziabad district have adequate"
39277889,Diagnostics Evaluation of Smart Sure™ Mycobacterium tuberculosis Screening Kit and Smart Sure™ Multidrug-resistant Tuberculosis Detection Kit on Nonsputum Specimens at a Tertiary Care Center of North India.,71.59; 98.28; 68.35; 90.83; 75.0; 100; 100,7,68.35,100.0,86.29285714285713,"ty of Smart Sure™ MTB screening kit was 71.59% and 98.28%, respectively, with Xpert ul | Sure™ MTB screening kit was 71.59% and 98.28%, respectively, with Xpert ultra and 68. | 28%, respectively, with Xpert ultra and 68.35% and 90.83%, respectively, with MGIT cul | tively, with Xpert ultra and 68.35% and 90.83%, respectively, with MGIT culture. While | Sure™ MDR-TB kits showed sensitivity of 75.0% and 100% of specificity. However, for i | TB kits showed sensitivity of 75.0% and 100% of specificity. However, for isoniazid | istance, Smart Sure™ MDR-TB kits showed 100% of sensitivity and specificity with MGI"
39067958,"Treatment outcomes of multidrug resistant tuberculosis (MDR TB) treated with bedaquiline under programmatic management of drug resistant tuberculosis at a tertiary care hospital in Punjab, India.",52.9; 20; 11.6; 14.2; 0.12,5,0.12,52.9,19.764,"vely. Out of 155 patients enrolled, 82 (52.9 %) were cured, 31 (20 %) completed treatm | s enrolled, 82 (52.9 %) were cured, 31 (20 %) completed treatment, 18 (11.6 %) defau | red, 31 (20 %) completed treatment, 18 (11.6 %) defaulted, 22 (14.2 %) died and 2 (0.1 | d treatment, 18 (11.6 %) defaulted, 22 (14.2 %) died and 2 (0.12 %) failed treatment. | 6 %) defaulted, 22 (14.2 %) died and 2 (0.12 %) failed treatment. Bdq is well tolerate"
39067941,Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study.,42.45; 50; 44.45; 33.33; 22.22; 93.33; 6.67; 4.44; 4.44; 37.78; 42.22; 20; 6.67; 93.33,14,4.44,93.33,35.809285714285714,"viduals with the disease. Of these, 45 (42.45%) experienced linezolid ADRs, with an in | ears) and more likely to be female (27, 50%) than those without ADRs. ADR severity | hout ADRs. ADR severity was mild in 20 (44.45%), moderate in 15 (33.33%), and severe i | as mild in 20 (44.45%), moderate in 15 (33.33%), and severe in 10 (22.22%) patients. T | erate in 15 (33.33%), and severe in 10 (22.22%) patients. The most common ADR was peri | mmon ADR was peripheral neuropathy (42, 93.33%), followed by lactic acidosis (3, 6.67% | 3.33%), followed by lactic acidosis (3, 6.67%), anemia (2, 4.44%), and optic neuritis | lactic acidosis (3, 6.67%), anemia (2, 4.44%), and optic neuritis (2, 4.44%). Dosing | emia (2, 4.44%), and optic neuritis (2, 4.44%). Dosing was reduced in 17 (37.78%) pat | s (2, 4.44%). Dosing was reduced in 17 (37.78%) patients, and linezolid was withdrawn | linezolid was withdrawn entirely in 19 (42.22%) patients. Only 9 (20%) patients contin | tirely in 19 (42.22%) patients. Only 9 (20%) patients continued linezolid unmodifie | ADR symptoms resolved completely in 4 (6.67%) patients and decreased in 42 (93.33%) | 4 (6.67%) patients and decreased in 42 (93.33%) patients. Linezolid ADRs, often neurop"
37968050,Comparison of gastric lavage/sputum and stool specimens in the diagnosis of pediatric pulmonary tuberculosis- A pilot study.,11; 5.65; 26,3,5.65,26.0,14.216666666666667,"Global TB report 2021 mentions 11 % prevalence of pediatric TB, whereas 5.6 | 1 % prevalence of pediatric TB, whereas 5.65% of the cases were reported from India i | esistance was detected in 13 of the 50 (26%) GL/SP specimens. Of these 13 children,"
37919487,Current Epidemiology of Pediatric Tuberculosis.,31; 7; 56; 3,4,3.0,56.0,24.25,"in children, which accounts for around 31% of the global pediatric TB load. Howeve | y, children have consistently made up 6-7% of all patients treated yearly under th | There is an estimated detection gap of 56% in India, which is the reason for many | ny missed cases of TB in children. Only 3% of children less than 14 y with MDR/RR-"
37724763,The Impact of Preventive Treatment for Multidrug- and Rifampin-Resistant Tuberculosis Exceeds Trial-Based Estimates.,70; 72; 45; 100,4,45.0,100.0,71.75,"TPT regimen (assuming 6-month duration, 70% efficacy) and associated active case fi | ial, MDR/RR-TPT was measured to prevent 72% (interquartile range, 45%-100%) of inci | ed to prevent 72% (interquartile range, 45%-100%) of incident MDR/RR-TB among recip | o prevent 72% (interquartile range, 45%-100%) of incident MDR/RR-TB among recipients"
37636185,Prospective study on outcome of MDR-TB using the shorter regimen during COVID-19 pandemic.,85; 75; 65.2; 39.3; 34.8; 8.9; 0.2,7,0.2,85.0,44.05714285714286,"B cases were detected in India, 56,569 (85%) were put on treatment, and 40,397 (75% | 85%) were put on treatment, and 40,397 (75%) were initiated on shorter drug regimen | uccess rate using a shorter regimen was 65.2% which is respectable, given the COVID-1 | d. Minor adverse events such as nausea (39.3%) and vomiting (34.8%) were reported. Ra | ts such as nausea (39.3%) and vomiting (34.8%) were reported. Rare adverse effects su | e adverse effects such as hearing loss (8.9%) and hypothyroidism (0.2%) were also se | hearing loss (8.9%) and hypothyroidism (0.2%) were also seen in the study population"
37406039,Maternal Colonization Versus Nosocomial Transmission as the Source of Drug-Resistant Bloodstream Infection in an Indian Neonatal Intensive Care Unit: A Prospective Cohort Study.,9.3; 47.7; 23.8; 47.7; 57,5,9.3,57.0,37.1,"onates required NICU admission, and 24 (9.3%) developed BSI. Among mothers of neonat | s of neonates with GN BSI (n = 21), 10 (47.7%) had rectal, 5 (23.8%) had vaginal, and | BSI (n = 21), 10 (47.7%) had rectal, 5 (23.8%) had vaginal, and 10 (47.7%) had no col | rectal, 5 (23.8%) had vaginal, and 10 (47.7%) had no colonization with resistant GN | of 51 BSI with available NGS data, 21 (57%) showed a single nucleotide polymorphis"
37234098,Studying the efficacy of isolation as a control strategy and elimination of tuberculosis in India: A mathematical model.,47; 22; 95; 50,4,22.0,95.0,53.5,"n, which was 1.5 million in 2009. About 47% increment in TB case notification in In | health problem. India contributes about 22% of the World's TB burden. Indian Nation | tment success rate could be achieved to 95%, by contact tracing and isolating at le | contact tracing and isolating at least 50% of MDR-TB."
36962909,"Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis.",3,1,3.0,3.0,3.0,zon. Costs and DALYs were discounted at 3% in the base case. Parameter uncertainty
36740313,Need to reinvigorateTuberculosis research in India - A review of studies registered under clinical trial registry of India.,0.58; 42.2; 50; 19.4; 7.8; 10; 8.9,7,0.58,50.0,19.84,"e registered in CTRI, with 180 studies (0.58%) being related to tuberculosis. Of thes | to tuberculosis. Of these studies, 76 (42.2%) were interventional in nature. These c | g different management or treatment TB (50%, n = 90), diagnostic studies (19.4%, n | t TB (50%, n = 90), diagnostic studies (19.4%, n = 35) and studies related to screeni | ated to screening and prevention of TB (7.8%, n = 14). Maximum studies were conducte | e safety and efficacy of anti-TB drugs (10%, n = 18) and to evaluate efficacy of sh | of shortening of duration of treatment (8.9%, n = 16). The studies related to extra"
36272707,Whole-genome sequencing of presumptive MDR-TB isolates from a tertiary healthcare setting in Mumbai.,93; 73; 97; 89; 63,5,63.0,97.0,83.0,"were observed in the rpoB gene (n = 93, 93%), wherein the Ser450Leu was the predomi | u was the predominant mutation (n = 68, 73%). Ser315Thr was the most common variant | hr was the most common variant (n = 86, 97%) that encoded resistance to isoniazid. | third most predominant variant (n = 65, 89%). In addition to the high levels of res | proportion of Beijing strains (n = 63, 63%). Compared with results from routine di"
36200688,Factors affecting the treatment outcome of injection based shorter MDR-TB regimen at a referral centre in India.,50.91; 49.09,2,49.09,50.91,50.0,"otal of 55 patients were enrolled, with 50.91% being successful (cured/treatment compl | cessful (cured/treatment completed) and 49.09% failing (including failure, lost to fol"
35989319,High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.,36; 69.2; 4.4; 57.8; 79; 40; 90.6,7,4.4,90.6,53.857142857142854,"bal MDR tuberculosis (TB) burden. About 36% of the MDR MTBC strains are reported fl | TBC strains were MDR, out of which 703 (69.2%) were pre-XDR and 45 (4.4%) were XDR. C | which 703 (69.2%) were pre-XDR and 45 (4.4%) were XDR. Cluster rates were high amon | XDR. Cluster rates were high among MDR (57.8%) and pre-XDR/XDR (79%) strains with thr | high among MDR (57.8%) and pre-XDR/XDR (79%) strains with three dominant L2 (Beijin | 3) representing half of the pre-XDR and 40% of the XDR-TB cases. L2 strains were as | irst-line and FQ resistance rates (81.6-90.6%). Epidemic success analysis using THD s"
35760485,"Health-related quality of life of multidrug-resistant tuberculosis patients: A study of eastern Uttar Pradesh, India.",45.85,1,45.85,45.85,45.85,7 patients were included in the study & 45.85% were dissatisfied with their condition.
35435077,"Spoligotyping of Mycobacterium tuberculosis isolates from Pulmonary Tuberculosis patients from North Karnataka, India.",27,1,27.0,27.0,27.0,control programmes. India accounts for 27% TB cases worldwide. Our study was under
35044136,"Determinants, risk factors and spatial analysis of multi-drug resistant pulmonary tuberculosis in Jodhpur, India.",23; 4.7,2,4.7,23.0,13.85,"plification test) were performed. 2898 (23%) showed M. TB positive but rifampicin s | tive but rifampicin sensitive, and 590 (4.7%) showed rifampicin resistant. Independe"
34752317,Drug resistance pattern and mutation pattern in pediatric tuberculosis: Study from north India.,61.1; 15.2; 34.2; 88; 84.6,5,15.2,88.0,56.620000000000005,"ce by Hain's GenoType MTBDRplus VER 2.0.61.1% were sensitive to isoniazid and rifampi | itive to isoniazid and rifampicin while 15.2% were DR-TB (38 out of 250). Out of thes | DR TB, 13 were isoniazid monoresistant (34.2%) and 3 were rifampicin monoresistant. T | 8 band and presence of rpoB MUT 3 band (88%). 84.6% of the INH monoresistant isolat | and presence of rpoB MUT 3 band (88%). 84.6% of the INH monoresistant isolates showe"
34752313,Prevalence of depression and anxiety among drug resistant tuberculosis: A study in North India.,68; 78; 54; 66,4,54.0,78.0,66.5,e of depression in MDR-TB and XDR-TB is 68% and 78% respectively. The prevalence of | ression in MDR-TB and XDR-TB is 68% and 78% respectively. The prevalence of anxiety | pectively. The prevalence of anxiety is 54% in MDR-TB and 66% in XDR-TB respectivel | valence of anxiety is 54% in MDR-TB and 66% in XDR-TB respectively in our study. Du
34637049,Mycobacterium tuberculosis strain lineage in mixed tribal population across India and Andaman Nicobar Island.,8.6; 15.4,2,8.6,15.4,12.0,he tribal population constitutes almost 8.6% of the nation's total population. Despi | ity testing (DST) results showed almost 15.4% of clinical isolates found to be resist
34446022,"Direct detection of resistance to fluoroquinolones/SLIDs in sputum specimen by GenoType MTBDRsl v.2.0 assay A study from Eastern Uttar Pradesh, India.",20; 26.6; 57.3; 15.9; 17; 61.3; 21.3; 92.31; 100; 100,10,15.9,100.0,51.171,"for GenoType MTBDRsl v.2.0 assay. While 20% of the decontaminated specimens were in | v.2.0 assay. Of the 1178 MTBC positive, 26.6% were sensitive to both FQs and SLIDs, w | ensitive to both FQs and SLIDs, whereas 57.3% were only FQs resistant and 15.9% were | ereas 57.3% were only FQs resistant and 15.9% were resistant to both FQs and SLIDs. F | isolates by liquid culture showed that 17% were sensitive to both FQs and SLIDs, 6 | % were sensitive to both FQs and SLIDs, 61.3% were only FQs resistant and 21.3% were | LIDs, 61.3% were only FQs resistant and 21.3% were resistant to both. The specificity | . The specificity for FQs and SLIDs was 92.31% and 100% whereas sensitivity was 100% r | ficity for FQs and SLIDs was 92.31% and 100% whereas sensitivity was 100% respective | 92.31% and 100% whereas sensitivity was 100% respectively by GenoType MTBDRsl v.2.0"
34343039,Pattern of Drug Resistance in Primary Spinal Tuberculosis: A Single-Center Study From India.,50; 24; 28.6; 16.2; 20.9; 9.3,6,9.3,50.0,24.833333333333332,"Spinal tuberculosis accounts for about 50% of cases among extra pulmonary osteoart | ce in Indian subcontinent which harbors 24% of global prevalence. The aim was to st | in spinal tuberculosis was found to be 28.6%. Of these, MDR was in 16.2%, pre-XDR in | found to be 28.6%. Of these, MDR was in 16.2%, pre-XDR in 20.9%, and XDR in 9.3% pati | Of these, MDR was in 16.2%, pre-XDR in 20.9%, and XDR in 9.3% patients. | in 16.2%, pre-XDR in 20.9%, and XDR in 9.3% patients."
33632218,The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.,50; 71; 72; 31; 44; 49; 21,7,21.0,72.0,48.285714285714285,"conferring 10 years of protection, with 50% efficacy. We measured vaccine cost-effe | ine reduced RR/MDR-TB incidence rate by 71% (UI: 69-72) and 72% (UI: 70-74), and th | B incidence rate by 71% (UI: 69-72) and 72% (UI: 70-74), and the PSI vaccine by 31% | 72% (UI: 70-74), and the PSI vaccine by 31% (UI: 30-32) and 44% (UI: 42-47) in Chin | the PSI vaccine by 31% (UI: 30-32) and 44% (UI: 42-47) in China and India, respect | ective at the lower HCOC threshold with 49% probability and PSI vaccines at the upp | ccines at the upper HCOC threshold with 21% probability. The P&PI vaccine was predi"
33600431,"Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.",6; 72; 74; 58; 42; 62; 94; 60; 95; 95; 95,11,6.0,95.0,68.45454545454545,"otal of 268 patients were included; 16 (6%) of them were children (0-9 years). The | in-max) age was 17(4-19) years and 192 (72%) were females. Majority (199, 74%) had | 192 (72%) were females. Majority (199, 74%) had pulmonary TB. Most (58%) had MDR-T | rity (199, 74%) had pulmonary TB. Most (58%) had MDR-TB while 42% had fluoroquinolo | lmonary TB. Most (58%) had MDR-TB while 42% had fluoroquinolone-resistant TB. The m | was 3(3-4) months. Of 268 patients, 166(62%) had successful end-of-treatment outcom | rtion of successful treatment outcomes (94% versus 60%) compared to adolescents. Pa | ccessful treatment outcomes (94% versus 60%) compared to adolescents. Patients with | dernutrition [adjusted odds-ratio, aOR (95% Confidence Interval, 95%CI): 2.5 (1.3-4 | ds-ratio, aOR (95% Confidence Interval, 95%CI): 2.5 (1.3-4.8) or those with XDR-TB | .5 (1.3-4.8) or those with XDR-TB [aOR (95% CI): 4.3 (1.3-13.8)] had higher likelih"
33565479,"Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.",73; 42.6; 37.2; 36.2; 34; 33; 7.4; 8.5; 11.7; 13.8; 94.7; 80; 75; 64,14,7.4,94.7,43.65,"DR-TB. Sixty-nine patients with MDR-TB (73%) reported ADRs. Tingling (42.6%), heada | h MDR-TB (73%) reported ADRs. Tingling (42.6%), headache (37.2%), numbness (36.2%), d | orted ADRs. Tingling (42.6%), headache (37.2%), numbness (36.2%), dizziness (34%) and | ng (42.6%), headache (37.2%), numbness (36.2%), dizziness (34%) and nausea (33%) were | e (37.2%), numbness (36.2%), dizziness (34%) and nausea (33%) were the most common | ss (36.2%), dizziness (34%) and nausea (33%) were the most common ADRs. Of the 94 p | e most common ADRs. Of the 94 patients, 7.4% were compelled to think of discontinuin | continuing their treatment due to ADRs; 8.5% had discontinued Cat-I/Cat-II regimen i | inued Cat-I/Cat-II regimen in the past; 11.7% had discontinued their MDR-TB regimen i | inued their MDR-TB regimen in the past; 13.8% had their drug regimen changed due to A | ir drug regimen changed due to ADRs and 94.7% had good adherence to their current reg | to their current regimen (took at least 80% of their doses till date). ADRs were th | es till date). ADRs were the reason for 75% of the patients who discontinued their | ir Cat-I/Cat-II regimen in the past and 64% of the patients who discontinued their"
33067551,Prevalence and factors associated with multidrug-resistant tuberculosis in South India.,5.4; 2.5; 11.4; 38; 29.3; 32.7; 59.4; 72.5; 27.5; 42.9; 22.2; 17.3; 54.5; 40.7; 4.7; 95; 2.17595; 95; 95; 95; 95; 95; 95; 95; 95; 95; 8.4; 1.3,28,1.3,95.0,50.81699821428572,"niazid mono-resistant TB were found in 5.4%, 2.5%, and 11.4% cases of presumptive M | mono-resistant TB were found in 5.4%, 2.5%, and 11.4% cases of presumptive MDR-TB, | stant TB were found in 5.4%, 2.5%, and 11.4% cases of presumptive MDR-TB, respective | d resistance to Rifampicin was found in 38%, 29.3%, and 32.7% of the 1582 MDR cases | istance to Rifampicin was found in 38%, 29.3%, and 32.7% of the 1582 MDR cases, respe | Rifampicin was found in 38%, 29.3%, and 32.7% of the 1582 MDR cases, respectively. S4 | he most common rpoB mutation present in 59.4% of the Rifampicin resistant cases. Of t | Of the 3390 Isoniazid resistant cases, 72.5% had mutations in the katG gene, and 27. | .5% had mutations in the katG gene, and 27.5% had mutations in the inhA gene. True re | , and inferred resistance accounted for 42.9%, 22.2%, and 17.3% of the 2459 katG resi | nferred resistance accounted for 42.9%, 22.2%, and 17.3% of the 2459 katG resistant c | istance accounted for 42.9%, 22.2%, and 17.3% of the 2459 katG resistant cases, respe | istance for the inhA gene were found in 54.5%, 40.7%, and 4.7% cases, respectively. M | for the inhA gene were found in 54.5%, 40.7%, and 4.7% cases, respectively. MDR-cont | hA gene were found in 54.5%, 40.7%, and 4.7% cases, respectively. MDR-contact (AOR 3 | s, respectively. MDR-contact (AOR 3.171 95% CI: 1.747-5.754, p-0.000) treatment fai | -5.754, p-0.000) treatment failure (AOR 2.17595% CI: 1.703-2.777, p-0.000) and female ge | , p-0.000) and female gender (AOR 1.315 95% CI: 1.117-1.548, p-0.001), were positiv | ositive association with MDR (AOR 1.113 95% CI: 0.801-1.546, p-0.523). Old age (AOR | 801-1.546, p-0.523). Old age (AOR 0.994 95% CI: 0.990-0.999, p-0.023) and HIV serop | .023) and HIV seropositivity (AOR 0.580 95% CI: 0.369-0.911, p-0.018) were negative | ation with treatment failure (AOR 2.509 95% CI: 1.804-3.490, p < .001), it did not | n with previous TB treatment (AOR 1.286 95% CI: 0.765-2.164, p-0.342) or with histo | story of contact with MDR-TB (AOR 1.813 95% CI: 0.591-5.560, p-0.298). However, INH | history of treatment for TB (AOR 1.303 95% CI: 1.021-1.662, p-0.033). It was also | s also positively associated (AOR 2.094 95% CI: 1.236-3.548, p-0.006) with MDR-TB c | shows a decrease in MDR prevalence from 8.4% in 2015 to 1.3% in 2018. A similar tren | in MDR prevalence from 8.4% in 2015 to 1.3% in 2018. A similar trend is observed fo"
33062976,"Profile of HIV and multidrug-resistant tuberculosis in orphans living in orphanages in Mumbai, Maharashtra, India.",61.1; 38.9; 3.5; 5.5,4,3.5,61.1,27.25,"en in orphanage A, boys constituted 11 (61.1%) and girls were 7 (38.9%), whereas orph | onstituted 11 (61.1%) and girls were 7 (38.9%), whereas orphanage B had all girls ( C | rphanages, with prevalence ranging from 3.5% to 5.5%. | s, with prevalence ranging from 3.5% to 5.5%."
32862166,High degree of fluoroquinolone resistance among extrapulmonary tuberculosis patients at a tertiary care center in North India.,20.4; 4.3,2,4.3,20.4,12.35,. Monoresistance of FQs was observed in 20.4% (11/54) among RR/MDR-TB isolates and 4. | 4% (11/54) among RR/MDR-TB isolates and 4.3% (15/348) among FLD-sensitive isolates.
32719234,"Trends & treatment outcomes of multidrug-resistant tuberculosis in Delhi, India (2009-2014): A retrospective record-based study.",59.12; 53.28,2,53.28,59.12,56.2,"from the treatment cards, of whom 1749 (59.12%) were males. The mean (±standard deviat | eatment outcomes were reported in 1371 (53.28%) patients, but they showed a declining"
32461400,Genotype analysis of ofloxacin-resistant multidrug-resistant Mycobacterium tuberculosis isolates in a multicentered study from India.,6.25; 44.44; 29.27; 30.15; 62.86; 5.71,6,5.71,62.86,29.78,"and spoligotyping, respectively. Three (6.25%), 12 (44.44%) and 12 (29.27%) MDR-TB is | yping, respectively. Three (6.25%), 12 (44.44%) and 12 (29.27%) MDR-TB isolates from w | ely. Three (6.25%), 12 (44.44%) and 12 (29.27%) MDR-TB isolates from western, northern | stant MDR-TB cases (P <0.05). Among 35 (30.15%) phenotypically OFX-resistant isolates, | notypically OFX-resistant isolates, 22 (62.86%) had mutations in the gyrA gene and two | had mutations in the gyrA gene and two (5.71%) isolates had mutations in the gyrB gen"
32218585,The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis.,23.9; 95; 30.8; 2.30; 95; 3.48; 95,7,2.3,95.0,49.354285714285716,"e the annual incidence of TB in 2030 by 23.9% [95% Bayesian credible intervals [CrI] | nnual incidence of TB in 2030 by 23.9% [95% Bayesian credible intervals [CrI] 17.6- | Bayesian credible intervals [CrI] 17.6-30.8%] if used to treat all TB cases, and by | ] if used to treat all TB cases, and by 2.30% [95% CrI 1.57-3.48%] if used to treat o | ed to treat all TB cases, and by 2.30% [95% CrI 1.57-3.48%] if used to treat only R | ll TB cases, and by 2.30% [95% CrI 1.57-3.48%] if used to treat only RR-TB. Notably, | th a regimen costing less than USD 359 (95% CrI 287-441), treating all diagnosed TB"
32192619,High prevalence of rifampin-resistant tuberculosis in mountainous districts of India.,85; 18; 10; 15; 36; 40; 15; 95,8,10.0,95.0,39.25,"atients enrolled (median age: 45 years; 85% males), 18% (n = 68) were rifampin-resi | lled (median age: 45 years; 85% males), 18% (n = 68) were rifampin-resistant. Among | (n = 305), distributions of RR-TB were: 10% (n = 9/89) for recurrent cases who had | ad received TB treatment for <2-months, 15% each for new (n = 9/59) or recurrent ca | ve between 2 and 4 months of treatment, 36% (n = 41/113) for treatment failures, an | n = 41/113) for treatment failures, and 40% (n = 2/5) for loss to follow-ups. Of th | low-ups. Of the sputum-smear positives, 15% (n = 51/338) were Xpert negative. Seeki | ted with higher risk of RR-TB (OR:1.85; 95% CI:0.87-3.9). Prevalence of RR-TB is ge"
32192613,Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.,50; 56; 89; 39; 57,5,39.0,89.0,58.2,t tuberculosis (MDR-TB); with less than 50% having successful treatment outcomes. B | undred and twenty MDR-TB patients [349 (56%) males; 554 (89%) between 18 and 50 yea | MDR-TB patients [349 (56%) males; 554 (89%) between 18 and 50 years and 240 (39%) | (89%) between 18 and 50 years and 240 (39%) severely malnourished] were started on | n June 2016 and August 2017. There 354 (57%) patients had MDR-TB with additional dr
32130233,Performance of Genotype MTBDRsl V2.0 over the Genotype MTBDRsl V1 for detection of second line drug resistance: An Indian perspective.,34.5; 6.2; 38.6; 85.7; 71.4; 28.5; 35.4; 5.3; 34.5; 4.4; 100,11,4.4,100.0,40.40909090909091,"B isolates. The results showed that 39 (34.5%) of these isolates were resistant to FQ | se isolates were resistant to FQ and 7 (6.2%) were XDR by Genotype MTBDRsl V2.0. Amo | t prevalent mutation was ΔWT3-D94G (17; 38.6%) and N538D (12; 85.7%). Among the AG/CP | as ΔWT3-D94G (17; 38.6%) and N538D (12; 85.7%). Among the AG/CP and KAN resistant iso | n in the rrs region was ΔWT1-A1401G (5; 71.4%) and C-14T (2; 28.5%) in eis gene. Seco | as ΔWT1-A1401G (5; 71.4%) and C-14T (2; 28.5%) in eis gene. Second line Bactec MGIT-9 | econd line Bactec MGIT-960 detected 40 (35.4%) isolates as resistant to FQ and 6 (5.3 | .4%) isolates as resistant to FQ and 6 (5.3%) as XDR isolates, whereas Genotype MTBD | Genotype MTBDRsl V1.0 also detected 39 (34.5%) as resistant to FQ but missed 2 isolat | tes in correctly identifying as XDR (5; 4.4%). Thus, concordance of second line Bact | with Genotype MTBDRsl V2.0 was similar (100%) for FQ detection but it has improvised"
31742141,Prevalence of multidrug resistance tuberculosis in adult patients in India: A systematic review and meta-analysis.,95; 3; 95; 2; 5,5,2.0,95.0,40.0,"eSH words. Prevalence was reported with 95% confidence interval (CI). A separate an | y I MDR-TB prevalence in new cases were 3% (95% CI 2%-5%, I MDR-TB prevalence in p | MDR-TB prevalence in new cases were 3% (95% CI 2%-5%, I MDR-TB prevalence in previo | prevalence in new cases were 3% (95% CI 2%-5%, I MDR-TB prevalence in previously t | valence in new cases were 3% (95% CI 2%-5%, I MDR-TB prevalence in previously trea"
31571455,"Socio-demographic Profile of MDR-TB and XDR-TB Patients Admitted in DR-TB Centre, North India.",20; 3.5; 18; 2.8; 12; 8.5; 41.86; 45.10,8,2.8,45.1,18.97,"veloped TB in 2017. India accounted for 20 % of world cases. Globally, 3.5 % of new | nted for 20 % of world cases. Globally, 3.5 % of new cases and 18% of previously trea | cases. Globally, 3.5 % of new cases and 18% of previously treated cases had MDR-TB. | TB. Corresponding figures for India are 2.8 % and 12 %. Among cases of MDR-TB in 2017 | ponding figures for India are 2.8 % and 12 %. Among cases of MDR-TB in 2017, 8.5% we | nd 12 %. Among cases of MDR-TB in 2017, 8.5% were estimated to have XDR-TB. Drug res | ents were analyzed, which revealed 293 (41.86 %) patients of MDR-TB and 23 (45.10 %) pa | 93 (41.86 %) patients of MDR-TB and 23 (45.10 %) patients of XDR-TB in the age group of"
31439176,"Epidemiological and behavioural correlates of drug-resistant tuberculosis in a Tertiary Care Centre, Delhi, India.",79.2; 20.8; 66; 46; 32; 58; 87; 35,8,20.8,87.0,53.0,"tients were included in the study; 198 (79.2%) with multidrug-resistant (MDR-TB) and | th multidrug-resistant (MDR-TB) and 52 (20.8%) with extensively drug-resistant TB (XD | y drug-resistant TB (XDR-TB). Of these, 66% patients were male and 46% came from po | ). Of these, 66% patients were male and 46% came from poor socioeconomic background | e current diagnosis of DR-TB. While 81 (32%) took treatment from private practition | er during the first episode of TB, 146 (58%) received treatment exclusively at gove | at government health facilities. Almost 87% of DR-TB patients were previously treat | larity of treatment was reported by 88 (35%) patients. The study explores the epide"
31408508,Development and evaluation of novel bio-safe filter paper-based kits for sputum microscopy and transport to directly detect Mycobacterium tuberculosis and associated drug resistance.,7; 4; 16; 20; 90; 95; 96; 84; 95; 92; 83; 95; 93; 75; 95; 97; 93; 92,18,4.0,97.0,73.44444444444444,"a significant increase in positivity of 7% and 4% over ZN smear and LED-FM smear ( | ficant increase in positivity of 7% and 4% over ZN smear and LED-FM smear (p<0.05) | smear grade status (1+ or 2+ to 3+) of 16% over ZN smear and 20% over LED-FM smear | + or 2+ to 3+) of 16% over ZN smear and 20% over LED-FM smear. The sensitivity of M | e MDR-TB and XDR-TB cases (n = 148) was 90% for Rifampicin (95% confidence interval | cases (n = 148) was 90% for Rifampicin (95% confidence interval [CI], 78-96%), 84% | picin (95% confidence interval [CI], 78-96%), 84% for Isoniazid (95% CI, 72-92%), 8 | (95% confidence interval [CI], 78-96%), 84% for Isoniazid (95% CI, 72-92%), 83% for | erval [CI], 78-96%), 84% for Isoniazid (95% CI, 72-92%), 83% for Fluoroquinolones ( | 78-96%), 84% for Isoniazid (95% CI, 72-92%), 83% for Fluoroquinolones (95% CI, 66- | %), 84% for Isoniazid (95% CI, 72-92%), 83% for Fluoroquinolones (95% CI, 66-93%) a | CI, 72-92%), 83% for Fluoroquinolones (95% CI, 66-93%) and 75% for Aminoglycosides | ), 83% for Fluoroquinolones (95% CI, 66-93%) and 75% for Aminoglycosides (95% CI, 3 | r Fluoroquinolones (95% CI, 66-93%) and 75% for Aminoglycosides (95% CI, 35-97%), u | I, 66-93%) and 75% for Aminoglycosides (95% CI, 35-97%), using phenotypic DST as th | and 75% for Aminoglycosides (95% CI, 35-97%), using phenotypic DST as the reference | rence standard. Test specificity was 88-93% and concordance was ~89-92% (κ value 0. | city was 88-93% and concordance was ~89-92% (κ value 0.8-0.9). The patient-friendly"
31151497,Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.,10.12; 27.01; 25.0; 19.7; 13.3; 11.8; 8.2; 5.9; 4.8; 49.6; 40.8; 27.01,12,4.8,49.6,20.27,"n criteria. Ototoxicity was observed in 10.12% [349/3447] patients within 3.8 ± 2.6 mo | tiation and ototoxicity was observed in 27.01% (121/448) patients in these five studie | dies (high frequency loss: capreomycin, 25.0% [1/4 patients]; amikacin, 19.7% [12/61] | omycin, 25.0% [1/4 patients]; amikacin, 19.7% [12/61]; kanamycin, 13.3% [22/166]; str | s]; amikacin, 19.7% [12/61]; kanamycin, 13.3% [22/166]; streptomycin, 11.8% [2/17]; f | anamycin, 13.3% [22/166]; streptomycin, 11.8% [2/17]; flat loss: amikacin, 8.2% [5/61 | cin, 11.8% [2/17]; flat loss: amikacin, 8.2% [5/61]; streptomycin, 5.9% [1/17]; kana | s: amikacin, 8.2% [5/61]; streptomycin, 5.9% [1/17]; kanamycin 4.8% [8/166]). Most o | ]; streptomycin, 5.9% [1/17]; kanamycin 4.8% [8/166]). Most of the patients experien | toxicity were managed by discontinuing (49.6% [120/242]) or replacing SLI treatment ( | [120/242]) or replacing SLI treatment (40.8% [49/120]). The study identified high pr | city was monitored regularly using PTA (27.01%), warranting a need to develop unified"
31151492,Isoniazid mono-resistant tuberculosis: Time to take it seriously.,50.5; 67.3; 32.7; 51.9; 48.1; 65.4; 93.3; 58.8; 41.2; 84; 16; 54.2; 45.8; 78.8,14,16.0,93.3,56.285714285714285,"mes. Out of 103 DRTB patients enrolled, 50.5% (52/103) patients were diagnosed with i | id mono-resistant patients revealed:35 (67.3%) were males and 17 (32.7%) females. 27 | revealed:35 (67.3%) were males and 17 (32.7%) females. 27 (51.9%) patients were <30 | were males and 17 (32.7%) females. 27 (51.9%) patients were <30 years, 25 (48.1%) be | 27 (51.9%) patients were <30 years, 25 (48.1%) being ≥30 years of age. All patients w | patients were negative for HIV. 34/52 (65.4%) patients were declared cured, 15/52 we | ignificantly better in females (14/15 = 93.3%), with only 1/15 LTFU, than males (20/3 | ith only 1/15 LTFU, than males (20/34 = 58.8% cure, 14/34 = 41.2% LTFU), (p = 0.019). | than males (20/34 = 58.8% cure, 14/34 = 41.2% LTFU), (p = 0.019). Patients who were < | ignificantly better cure rates (21/25 = 84%) with lesser LTFU's (4/25 = 16%), than | 21/25 = 84%) with lesser LTFU's (4/25 = 16%), than those ≥30years of age (13/24 = 5 | %), than those ≥30years of age (13/24 = 54.2% cure, 11/24 = 45.8% LTFU), (p = 0.032). | ars of age (13/24 = 54.2% cure, 11/24 = 45.8% LTFU), (p = 0.032). Review of previous | niazid mono-resistant patients (26/33 = 78.8%), than those with previous history of b"
31114100,"A Survey of Medical Professionals in an Apex Tertiary Care Hospital to Assess Awareness, Interest, Practices, and Knowledge in Palliative Care: A Descriptive Cross-sectional Study.",56; 81; 77; 50.8; 88; 89.8; 50,7,50.0,89.8,70.37142857142858,"alliative care. Out of 186 respondents, 56% had not received any basic training in | any basic training in palliative care. 81% wanted palliative care education to be | on barrier in learning palliative care. 77% respondents had no idea about home base | ut home based palliative care services. 50.8% patients dies in hospital in their term | es in hospital in their terminal stage. 88% were interested in learning safe opioid | earning safe opioid practices. Although 89.8% were aware of the need of palliative ca | care in metastatic cancer but less than 50% were aware of the fact that palliative"
30797290,Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India.,70; 37; 5; 2.56; 68; 20; 78; 10; 40,9,2.56,78.0,36.72888888888889,"althcare is choice of point of care for 70% of Indians. Multidrug resistant tubercu | he major expense was due to drug costs (37%) while consultation fees were only 5%. | (37%) while consultation fees were only 5%. Annual individual income for the cohor | rage, the cost of treatment ranged from 2.56% to 180.34% of the annual family income. | 34% of the annual family income. 34/50 (68%) had total costs greater than 20% of an | 4/50 (68%) had total costs greater than 20% of annual family income and 39/50 (78%) | 20% of annual family income and 39/50 (78%) had total costs greater than 10% of an | 9/50 (78%) had total costs greater than 10% of annual family income. The number of | he number of patients with total costs >40% of total family income was 22. MDR-TB i"
30675322,Rapid detection of multidrug resistant tuberculosis in respiratory specimens at a tertiary care centre in south coastal Karnataka using Genotype MTBDR plus assay.,19.53; 12.50; 5.86; 4.3,4,4.3,19.53,10.5475,"TB were tested by GenoType MTBDR Fifty (19.53%) isolates were found MDR, 32 (12.50%) i | y (19.53%) isolates were found MDR, 32 (12.50%) isolates were found mono-resistant to | und mono-resistant to isoniazid and 15 (5.86%) isolates were found mono-resistant to | sistant to rifampicin. Eleven isolates (4.3%) were found NTM. Mutation in codon S531"
30668857,Genetic diversity of Mycobacterium tuberculosis Central Asian Strain isolates from Nepal and comparison with neighboring countries.,23.3,1,23.3,23.3,23.3,"f 14 isolates with a clustering rate of 23.3%, suggesting ongoing transmissions. Base"
30611735,"Spoligotyping, phenotypic and genotypic characterization of katG, rpoB gene of M. tuberculosis isolates from Sahariya tribe of Madhya Pradesh India.",12.6; 4.85; 8.7; 3.8; 3.85; 0.97,6,0.97,12.6,5.794999999999999,"ibility test identified high incidence (12.6%) of isoniazid-resistant tuberculosis, w | isoniazid-resistant tuberculosis, while 4.85% isolates were multi drug resistant (MDR | otyping of drug target genes identified 8.7% of isoniazid-R isolates to have a mutat | ave a mutation at katG codon 463, while 3.8% isolates showed mutations at two sites, | MDR-TB isolates, all from CAS lineage, 3.85% had mutations on katG and rpoB genes, a | 463 and codon 526, respectively, while 0.97% isolates were harbouring mutations at c"
30522617,"Delineating the factors associated with recurrence of tuberculosis in programmatic settings of rural health block, Himachal Pradesh, India.",14.2; 50.0; 47.4; 13.8; 2.3; 51.7; 14.5; 48.3; 72.1; 00.0; 13.4,11,0.0,72.1,29.79090909090909,"t TB (recurrent cases). Total 29 cases (14.2%) had recurrence (17.7/100,000 populatio | ion for alternate residence (Recurrent: 50.0%, Non-recurrent: 47.4%; p = 0.001), Mult | dence (Recurrent: 50.0%, Non-recurrent: 47.4%; p = 0.001), Multi-drug resistance (MDR | ti-drug resistance (MDR) TB (Recurrent: 13.8%, Non-recurrent: 2.3%; p = 0.003), and s | R) TB (Recurrent: 13.8%, Non-recurrent: 2.3%; p = 0.003), and sputum negative patien | nd sputum negative patients (Recurrent: 51.7%, Non-recurrent: 14.5%; p = 0.000). Non- | ients (Recurrent: 51.7%, Non-recurrent: 14.5%; p = 0.000). Non-recurrent cases had si | n for sputum positive cases (Recurrent: 48.3%, Non-recurrent: 72.1%; p = 0.011), and | cases (Recurrent: 48.3%, Non-recurrent: 72.1%; p = 0.011), and extra-pulmonary TB (Re | 11), and extra-pulmonary TB (Recurrent: 00.0%, Non-recurrent: 13.4%; p = 0.036). MFA | ry TB (Recurrent: 00.0%, Non-recurrent: 13.4%; p = 0.036). MFA observed all significa"
30531028,Profile of drug-resistant-conferring mutations among new and previously treated pulmonary tuberculosis cases from Aligarh region of Northern India.,11.02; 20.03; 71.43; 72.17; 100; 81.74; 7.8,7,7.8,100.0,52.027142857142856,"d cases by GenoType MDR-TB was detected 11.02%, 20.03% in new and previously treated c | by GenoType MDR-TB was detected 11.02%, 20.03% in new and previously treated cases. Am | common mutation detected in rpoB gene; 71.43% in new, and 72.17% in previously treate | tected in rpoB gene; 71.43% in new, and 72.17% in previously treated cases. S315T1 was | ost common mutation noted in katG gene; 100% in new and 81.74% in previously treated | ion noted in katG gene; 100% in new and 81.74% in previously treated. While in hA gene | treated. While in hA gene, it was C15T (7.8%) among previously treated cases. MDR-TB"
30319946,Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.,2.1; 15; 64.81; 69.44; 86.91; 50.93; 17.59; 18.51; 32.71; 34.42; 13.11; 8.1; 77.04,13,2.1,86.91,37.74384615384616,"n of multidrug-resistant TB (MDR-TB) is 2.1% (in new TB cases) and 15% (in previousl | (MDR-TB) is 2.1% (in new TB cases) and 15% (in previously treated cases). Programm | f total 108 patients majority patients (64.81%) were in young (20-39 years) with m:f: | DR-TB patients were retreated cases and 69.44% were ""undernutrition category"". Culture | category"". Culture conversion rate was 86.91% at 4 months of treatment. Cure rate was | at 4 months of treatment. Cure rate was 50.93% while defaulter rate and died rate was | defaulter rate and died rate was same (17.59%). Failure rate was 18.51%. Weight impro | ate was same (17.59%). Failure rate was 18.51%. Weight improvement was significantly a | ith cure rate. The incidence of ADR was 32.71%. Most frequent ADRs were related to gas | ere related to gastrointestinal system (34.42%), ototoxicity (13.11%), and central ner | ntestinal system (34.42%), ototoxicity (13.11%), and central nervous system (8.1%). Am | y (13.11%), and central nervous system (8.1%). Aminoglycosides, cycloserine, and eth | discontinued due to ADR. Majority ADRs (77.04%) were ""possible"" category by causality"
29933863,Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.,3; 17; 91.5; 1.8; 98.2; 45; 16.6; 98.5; 4.4; 44,10,1.8,98.5,42.0,"e prevalence of MDR-TB is known to be 2-3% among new TB patients and 12-17% in pre | to be 2-3% among new TB patients and 12-17% in previously treated patients, program | July 2011 and Sep 2013. Of these, 1602 (91.5%) MDR-TB patients were included in the s | patient. Of these, after excluding 87 (1.8%) contacts with past history of diagnosi | iagnosis and/or treatment for TB, 4771 (98.2%) contacts were screened for current sig | Their mean age was 28.5 years and 2151 (45%) were females. Of the 4771 contacts scr | es. Of the 4771 contacts screened, 793 (16.6%) had at least one of the symptoms sugge | symptoms suggestive of TB of whom 781 (98.5%) had two sputum specimen transported an | 781 symptomatic contacts examined, 34 (4.4%) were bacteriologically confirmed with | eriologically confirmed with TB and 15 (44%) also had Rif resistance (RR). High ext"
29933862,Cost effectiveness of decentralised care model for managing MDR-TB in India.,23; 94,2,23.0,94.0,58.5,the cost difference would range between 23% and 94% for the country. Our study prov | difference would range between 23% and 94% for the country. Our study provides evi
29933860,"Management practices of tuberculosis in children among pediatric practitioners in Mangalore, South India.",62; 50; 64; 22; 16; 52; 16; 52; 30; 72; 36,11,16.0,72.0,42.90909090909091,"tricians participated in the study with 62% having an attachment to the teaching in | to the teaching institution. More than 50% identified all the symptoms of TB. 64% | 50% identified all the symptoms of TB. 64% were sending chest X-ray, Mantoux test | tum examination for AFB to diagnose TB. 22% were not stressing for AFB examination. | ot stressing for AFB examination. Still 16% told serological tests as one of the di | ests as one of the diagnostic modality. 52% were not aware about the diagnosis of l | re about the diagnosis of latent TB. In 16% of their cases ATT was on a trial basis | ir cases ATT was on a trial basis. Only 52% of the clinicians are adhering to updat | to updated national (RNTCP) guidelines. 30% felt still there are drawbacks in the c | wbacks in the current RNTCP guidelines. 72% knew the correct definition of MDR tube | efinition of MDR tuberculosis. But only 36% of them knew the diagnostic method (gen"
29628698,Drug resistant Skeletal Tuberculosis in a tertiary care centre in South India.,10; 53.2; 46.8; 10.2; 4.7; 1.4; 3.7; 0.4; 66; 85; 3.7; 0.4,12,0.4,85.0,23.791666666666668,"s. Skeletal tuberculosis accounts up to 10% of all extra pulmonary tuberculosis. Wo | e period of 2006-2013 (96 months). 478 (53.2%) patients were treated for tubercular s | ted for tubercular spondylitis and 420 (46.8%) for extra-spinal skeletal tuberculosis | etal tuberculosis. Ninety two patients (10.2%) had documented resistance to the anti- | e 42 mono resistant tuberculosis cases (4.7%), 13 poly resistant cases (1.4%), 33 mu | cases (4.7%), 13 poly resistant cases (1.4%), 33 multi-drug resistant cases (MDR TB | 33 multi-drug resistant cases (MDR TB) (3.7%) and 4 (0.4%) extremely drug resistant | resistant cases (MDR TB) (3.7%) and 4 (0.4%) extremely drug resistant tuberculosis | ery was performed when indicated in 59 (66%) cases. 85% completed their course of t | ormed when indicated in 59 (66%) cases. 85% completed their course of treatment and | tuberculosis patients in our centre was 3.7% and that of Extremely drug resistant tu | y drug resistant tuberculosis cases was 0.4%. A Multi-disciplinary approach with dru"
29604431,Prevalence of mutations in genes associated with isoniazid resistance in Mycobacterium tuberculosis isolates from re-treated smear-positive pulmonary tuberculosis patients: A meta-analysis.,11.8; 71.0; 29.0; 89.1; 0.4; 10.5; 12.0; 10.8; 67.3; 95; 75.4,11,0.4,95.0,42.93636363636364,"inclusive of codon 315. In total, 1821 (11.8%) of 15438 INH-resistant strains had det | stant strains had detectable mutations: 71.0% in katG315 and 29.0% in the inhA promot | ectable mutations: 71.0% in katG315 and 29.0% in the inhA promoter region. The preval | he prevalence of IHN monoresistance was 89.1% in the economically-active age group, 0 | % in the economically-active age group, 0.4% in the paediatric age group and 10.5% i | p, 0.4% in the paediatric age group and 10.5% in those aged >60years; the rate in mal | ears; the rate in males and females was 12.0% and 10.8%, respectively. Meta-analysis | rate in males and females was 12.0% and 10.8%, respectively. Meta-analysis derived a | ed katGS315T resistant TB prevalence of 67.3% (95% CI 59.3-75.4%) with Q=732.19, I IN | S315T resistant TB prevalence of 67.3% (95% CI 59.3-75.4%) with Q=732.19, I INH res | ant TB prevalence of 67.3% (95% CI 59.3-75.4%) with Q=732.19, I INH resistance was sp"
29596221,"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome.",9.6; 5.6; 7; 20; 80; 28.18; 87.3; 12.7; 7.2; 6.3; 25.45; 29.09; 8.18; 10.9; 26.1; 60.8; 30.4; 47.6; 56.9; 8.7; 46; 57; 30; 19.09; 50.09,25,5.6,87.3,30.807199999999998,"valence of DR-TB was 110 of 1145 cases (9.6%), which showed an increase, compared wi | which showed an increase, compared with 5.6% pre-2010 and 7% in 2010-2013 (P = 0.014 | crease, compared with 5.6% pre-2010 and 7% in 2010-2013 (P = 0.014408). Twenty-two | 13 (P = 0.014408). Twenty-two children (20%) had pulmonary-TB and 88 (80%) had extr | children (20%) had pulmonary-TB and 88 (80%) had extra-pulmonary-TB with disseminat | ost common presentation in 31 children (28.18%). Ninety-six children (87.3%) were bact | children (28.18%). Ninety-six children (87.3%) were bacteriologically confirmed TB ca | iologically confirmed TB cases, and 14 (12.7%) were clinically diagnosed-TB and treat | reated as per contact DST. Eight cases (7.2%) were monoresistant, 7 (6.3%) polyresis | ght cases (7.2%) were monoresistant, 7 (6.3%) polyresistant, MDR-TB seen in 28 patie | yresistant, MDR-TB seen in 28 patients (25.45%), 32 (29.09%) had pre-XDR-TB, 9 (8.18%) | DR-TB seen in 28 patients (25.45%), 32 (29.09%) had pre-XDR-TB, 9 (8.18%) had XDR-TB a | 25.45%), 32 (29.09%) had pre-XDR-TB, 9 (8.18%) had XDR-TB and 12 (10.9%) were rifampi | re-XDR-TB, 9 (8.18%) had XDR-TB and 12 (10.9%) were rifampicin resistant. Ethionamide | . Ethionamide resistance increased from 26.1% pre-2013 to 60.8% post-2013 (P = 0.0144 | stance increased from 26.1% pre-2013 to 60.8% post-2013 (P = 0.014408) and ofloxacin | 408) and ofloxacin resistance rose from 30.4% pre-2010, to 47.6% in 2010-2013 and 56. | resistance rose from 30.4% pre-2010, to 47.6% in 2010-2013 and 56.9% post-2013 (P = 0 | .4% pre-2010, to 47.6% in 2010-2013 and 56.9% post-2013 (P = 0.080863). Moxifloxacin | in resistance showed an acute rise from 8.7% pre-2010, to 46% in 2010-2013 and 57% p | ed an acute rise from 8.7% pre-2010, to 46% in 2010-2013 and 57% post-2013 (P = 0.0 | 8.7% pre-2010, to 46% in 2010-2013 and 57% post-2013 (P = 0.000275). Thirty-three | (P = 0.000275). Thirty-three patients (30%) had completed their treatment, 21 (19. | 30%) had completed their treatment, 21 (19.09%) were lost to follow-up and 56 (50.09%) | (19.09%) were lost to follow-up and 56 (50.09%) patients are still on treatment. DR-TB"
29460737,"Use of Verbal Autopsy to Determine Underlying Cause of Death during Treatment of Multidrug-Resistant Tuberculosis, India.",50; 66,2,50.0,66.0,58.0,"idrug-resistant tuberculosis (MDR TB), <50% complete treatment. Most treatment fail | tain the underlying cause of death. For 66% of patient deaths (47/71), TB was the u"
28887289,Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India.,8.0; 32; 88; 32,4,8.0,88.0,40.0,"resistance was observed in 70 patients (8.0%), among which pre-existing FQ resistanc | -existing FQ resistance was detected in 32%. Moreover, 88% of isolates exhibited a | sistance was detected in 32%. Moreover, 88% of isolates exhibited a similar DST pat | X. A huge proportion of MDR-TB strains (32%) exhibiting OFX resistance prior to tre"
